Early Convalescent Plasma for High-Risk Outpatients with Covid-19.

ABSTRACT:

Background

Early administration of convalescent plasma obtained from blood donors who have recovered from coronavirus disease 2019 (Covid-19) may prevent disease progression in acutely ill, high-risk patients with Covid-19.

Methods

In this randomized, multicenter, single-blind trial, we assigned patients who were being treated in an emergency department for Covid-19 symptoms to receive either one unit of convalescent plasma with a high titer of antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or placebo. All the patients were either 50 years of age or older or had one or more risk factors for disease progression. In addition, all the patients presented to the emergency department within 7 days after symptom onset and were in stable condition fo

SUBMITTER: Korley FK 

PROVIDER: S-EPMC8385553 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature